section name header

Pronunciation

dox-AY-zoe-sin

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: peripherally acting antiadrenergics

Indications

BEERS REMS


Action

  • Dilates both arteries and veins by blocking postsynaptic alpha1-adrenergic receptors.
Therapeutic effects:
  • Lowering of BP.
  • Increased urine flow and decreased symptoms of BPH.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 98–99%.

Metabolism/Excretion: Extensively metabolized by the liver.

Half-Life: 22 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
PO1–2 hr2–6 hr24 hr
PO-XL5 wkunknownunknown

Antihypertensive effect.

Improved urinary flow and BPH symptoms.



Contraind./Precautions

Contraindicated in:

  • Hypersensitivity.

Use Cautiously in:

  • Hepatic impairment;
  • GI narrowing (XL only);
  • Patients undergoing cataract surgery ( risk of intraoperative floppy iris syndrome);
  • OB: Not a preferred antihypertensive during pregnancy ;
  • Pedi: Safety and effectiveness not established in children;
  • Geri: Appears on Beers list. risk of orthostatic hypotension in older adults. Avoid use for treatment of hypertension in older adults.

Adv. Reactions/Side Effects

CV: first-dose orthostatic hypotension, arrhythmias, chest pain, edema, palpitations

Derm: flushing, rash, urticaria

EENT: blurred vision, conjunctivitis, epistaxis, intraoperative floppy iris syndrome

GI: abdominal discomfort, constipation, diarrhea, dry mouth, flatulence, nausea, vomiting

GU: libido, priapism, sexual dysfunction

MS: arthralgia, myalgia

Neuro: dizziness, headache, depression, drowsiness, fatigue, nervousness, weakness.

Resp: dyspnea

Interactions

Drug-drug:

Route/Dosage

Hypertension

  • PO (Adults ): 1 mg once daily; may be gradually at 2-wk intervals to 2–16 mg/day; incidence of postural hypotension greatly at doses >4 mg/day.

Benign Prostatic Hyperplasia

  • PO (Adults ): Immediate release: 1 mg once daily; may be every 1–2 wk up to 8 mg/day; Extended release: 4 mg once daily (with breakfast); may be in 3–4 wk to 8 mg/day.

Availability

(Generic available)
  • Tablets: 1 mg; 2 mg; 4 mg; 8 mg
  • Extended-release tablets: 4 mg; 8 mg

Assessment

  • Monitor BP and HR 2–6 hr after 1st dose, with each in dose, and periodically during therapy. Report significant changes.
    • Assess for 1st dose orthostatic hypotension and syncope. Incidence may be dose related. Observe patient closely during this period and take precautions to prevent injury.
    • Monitor intake and output and daily weight, and assess for edema daily, especially at beginning of therapy. Report weight gain or edema.
  • BPH: Assess patient for symptoms of prostatic hyperplasia (urinary hesitancy, feeling of incomplete bladder emptying, interruption of urinary stream, impairment of size and force of urinary stream, terminal urinary dribbling, straining to start flow, dysuria, urgency) before and periodically during therapy.

Implementation

  • PO: Administer daily dose at bedtime.
    • DNC: XL tablets should be swallowed whole; do not break, crush, or chew.
  • Hypertension: May be administered concurrently with a diuretic or other antihypertensive.

Patient/Family Teaching

  • Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy. Emphasize the importance of continuing to take this medication, even if feeling well. Instruct to take at the same time each day. Take missed doses as soon as remembered unless almost time for next dose. Do not double doses.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to avoid concurrent use of alcohol or OTC medications and herbal products without consulting health care professional, especially cough, cold, or allergy remedies.
  • May cause drowsiness or dizziness. Advise patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Caution patient to change positions slowly to orthostatic hypotension. May cause syncopal episodes, especially within 1st 24 hr of therapy, with dose , and with resumption of therapy after interruption.
  • Advise patient to notify other physicians of drug therapy.
  • Advise male patient to notify health care professional if priapism or erection lasts >4 hr; may lead to permanent impotence if not treated.
  • Emphasize the importance of follow-up visits to determine effectiveness of therapy.
  • Hypertension: Instruct patient and caregiver on proper technique for BP monitoring. Advise them to check BP weekly and report significant changes.
    • Encourage patient to comply with additional interventions for hypertension (weight reduction, low-sodium diet, smoking cessation, moderation of alcohol consumption, regular exercise, stress management).
    • Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Lowering of BP.
  • Increased urine flow and decreased symptoms of BPH.

US Brand Names

Cardura, Cardura XL